MDNA Insider Trading (Medicenna Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$10,982.80
Insider Selling (Last 12 Months): C$0.00
Medicenna Therapeutics Share Price & Price History
Current Price: C$1.48
Price Change: ▼ Price Decrease of -0.08 (-5.13%)
As of 06/30/2022 01:00 AM ET
Former Lawyer Went From $50K To $5.3M Trading Options
From Investing Daily | Ad
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.
I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).
I grew my $50K into $5.3M
I'll show you how I did it here.
Medicenna Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/1/2021 | Elizabeth Williams | Senior Officer | Buy | 4,000 | C$2.75 | C$10,982.80 | 10,300 | |
This Has Won 99.1% Of Trades Over 3 Years
From Investing Daily | Ad
Video reveals the most powerful trade you’ve NEVER heard of. Released every Tuesday, it could DOUBLE your money by Friday.
In past 3 years, it’s won 321 out of 324 of these trades, with the majority making 100%+ every 3-10 days.
See how a simple 10-minute trade on Tue could double your money by Fri.
Watch Video Now For Full Details.
>>>
SEC Filings (Institutional Ownership Changes) for Medicenna Therapeutics (TSE:MDNA)
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Read More on Medicenna Therapeutics
Today's Range
Now: C$1.48
52 Week Range
Now: C$1.48
Volume
17,450 shs
Average Volume
29,977 shs
Market Capitalization
C$83.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Medicenna Therapeutics?
